Acute promyelocytic leukemia after iodine-131 therapy for Graves' disease.
Graves' disease is an autoimmune process in which the thyroid gland is stimulated by autoantibodies, leading to hyperthyroidism. Graves' disease is the most common cause of hyperthyroid function, primarily affecting women in their 40s and 50s. Treatment may involve oral radioiodine, which is taken up by the follicular cells of the thyroid, where it emits ionizing radiation to promote destruction of those cells. Radioiodine therapy is typically safe, effective, and inexpensive. We describe the case of a 51-year-old woman who developed acute promyelocytic leukemia within 27 months of completing a cumulative dose of radioiodine 22.1 mCi (817.7 MBq) for treatment of Graves' disease. Assessment of causality using the Naranjo probability scale showed that a possible relationship existed between this patient's acute promyelocytic leukemia and the use of radioiodine. Strict hematologic follow-up of patients treated with radioiodine may be warranted, along with a high index of suspicion in those with coagulopathy.
Kolade
Victor O
VO
Department of Medicine, Erie County Medical Center, Buffalo, New York 14215, USA. vkolade@buffalo.edu
Bosinski
Timothy J
TJ
Ruffy
Enrico L
EL
D005260:Female; D006111:Graves Disease / Q000188:drug therapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects* / Q000627:therapeutic use; D015473:Leukemia, Promyelocytic, Acute / Q000139:chemically induced*; D008875:Middle Aged; D019275:Radiopharmaceuticals / Q000009:adverse effects*
D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals